Renovaro Biosciences Denmark ApS: Financial statements 2020
CVR: 26027322
Source: annual report 2020, Danish Business Authority
01/07/2019 – 30/06/2020
Renovaro Biosciences Denmark ApS (CVR 26027322) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK -1,113,727 and a net result of DKK -1,708,076 compared with DKK -6,845,472 the year before. Equity in the 2020 report amounted to DKK -64,346,720. The company had 1 employee in the financial year.
- Gross Profit
- DKK -1,113,727
- Profit/Loss
- DKK -1,708,076
- Equity
- DKK -64,346,720
- Total Assets
- DKK 5,680,351
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | -1.1M | -1.7M | -64.3M | 1 |
| 2019 | - | -1.9M | -6.8M | -62.6M | 1 |
| 2018 | - | -4.5M | -7M | -55.8M | - |
| 2016 | - | -5M | -10.7M | -52M | 2 |
| 2015 | - | -17.4M | -20.4M | -41.3M | - |
Official annual report
How creditworthy is Renovaro Biosciences Denmark ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreAbout Renovaro Biosciences Denmark ApS
Renovaro Biosciences Denmark ApS is a Danish company of the type Anpartsselskab based in Hørsholm, founded in 2001. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Enochian BioSciences Denmark ApS and DanDrit Biotech ApS. The management consists of David Hershel Weinstein. The company is owned by Lunai Bioworks Inc.. The company has 1 employee (2017). In 2026, the company reported a gross profit of DKK -4,478 and a net result of DKK -1,178,038 compared with DKK -4,629,959 the year before. Equity in the 2026 report amounted to DKK -91,933,986.
